Although patients with relapsed or refractory multiple myeloma now have more treatment options than ever, their journeys are often complex. As clinicians consider when to introduce newer therapies such as bispecific antibodies, they must account for prior treatments, treatment-related toxicities, and comorbidities that may impact treatment decisions.
The treatment landscape for relapsed or refractory multiple myeloma (RRMM) is advancing at a remarkable pace, with additional therapies expanding options for patients across the continuum of care.1 Among these are bispecific antibodies, which redirect the patient’s own T cells to target malignant myeloma cells.2 With four FDA-approved options currently available, the bispecific class is becoming a larger part of the treatment conversation.3
For community oncology teams, the adoption of these therapies brings both excitement and challenges.4 Identifying appropriate candidates, managing unique toxicities, and coordinating care across specialties and care settings all require thoughtful planning and collaboration.4 Many cancer programs also need strategies for ensuring continuity of care when patients transition between academic and community centers.4
Bispecific antibody-based treatments represent additional options for patients with RRMM.4 They offer hope for patients at different stages in their disease by targeting RRMM in a different way2—but their use requires education, planning, and teamwork.4 Although patients with RRMM now have more treatment options than ever, their journeys are often complex. As clinicians consider when to introduce newer therapies such as bispecific antibodies, they must account for prior treatments, treatment-related toxicities, and comorbidities that may impact treatment decisions.5 These realities underscore the importance of individualized care, multidisciplinary support, and careful treatment selection at every stage of a patient’s journey.
Community oncology clinicians are on the front lines of delivering this care and balancing the latest scientific advances with the day-to-day realities of their practice.4 While clinical trial data highlight the potential benefits and risks of bispecific antibodies, real-world implementation raises questions that go beyond efficacy and safety.4 How do clinicians identify the right patient at the right time? What systems can be put in place to monitor for and manage adverse reactions, help ensure adherence, and support patients holistically? How can teams strengthen academic-community partnerships to streamline transitions of care when referrals are needed?
Community oncology clinicians are positioned to deliver these therapies close to where patients live, provided they have access to practical tools, resources, and collaborative support,4 and that is where the Association of Cancer Care Centers (ACCC) can help.
ACCC will publish an article in its official journal, Oncology Issues, which highlights real-world expert perspectives on integrating a bispecific antibody into community practice and provides insight into a new treatment approach recently approved by the FDA for patients. Designed specifically with the community oncology audience in mind, the Oncology Issues article will focus on Allegheny Health Network’s (AHN) real-world strategies and experience with adopting a bispecific antibody in RRMM care. This multidisciplinary cancer care team will share their perspectives on integrating bispecific antibody therapies within the context of everyday clinical practice and provide a broader look at establishing workflows and protocols that could allow these treatments to be mapped into existing pathways.
ACCC is excited to publish this article. In the meantime, consider sharing this resource with colleagues who are eager to strengthen their approach to treating patients with RRMM. With continued collaboration, community and academic oncology teams can work together to expand access to these therapies and deliver care that is close to home for this patient population.
Developed under the direction and sponsorship of Johnson & Johnson
© Johnson & Johnson and its affiliates 2026 06/26 cp-546867v1
